Year-end Sale % OFF 
Abstract
Chronic hepatitis B infection remains a relatively common disease in European hepatology and gastroenterology practice. Current treatment guidelines in Europe discuss pegylated interferon-α or nucleoside analogues in treating chronic hepatitis B. The indications and the necessity for treatment are based mainly on the combination of three criteria: serum hepatitis B virus DNA concentrations, serum aminotransferase levels, and histologic grade and stage. The advent of potent nucleoside analogues with low rates of resistance has potentially simplified treatment. The pipeline of new agents to treat hepatitis B remains restricted, and cross-resistance is shared by several nucleosides. Thus, the guidelines emphasize the advantage and necessity of using potent agents with low rates of resistance as optimal therapy to avoid difficult-to-treat, multidrug-resistant hepatitis B.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
